The agency concluded that for people of all ages, IXCHI should be administered when there is a significant risk of chikungunya infection
The submission is based on data from the STEP UP and STEP UP T2D clinical trials
Masitinib is targeted at patients who are no longer responding to hormone-sensitive prostate cancer treatments
These medicines are essential in preventing RhD immunisation during pregnancy
New findings reveal bemarituzumab plus chemotherapy significantly improves survival in advanced gastric cancer, offering hope for targeted treatment options
Review will evaluate effectiveness in treating alcohol withdrawal syndrome and supporting abstinence, as well as measures to mitigate risk of abuse
The Swiss peptide and oligonucleotide manufacturers roll out major investments across site networks in US, UK and Switzerland
The transaction is expected to close in Q2 FY 2026
The acquisition sets up the foundation for a central hub of GMP value-added services and greater access to new customers in the rapidly growing Biopharma market
Globally, BRUKINSA is approved in more than 70 countries
Subscribe To Our Newsletter & Stay Updated
